Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits

BACKGROUND: To help BRCA1 and 2 mutation carriers make informed decisions regarding use of combined-type oral contraceptive preparation (COCP), absolute risk-benefit estimates are needed for COCP-associated cancer. METHODS: For a hypothetical cohort of 10 000 women, we calculated the increased or de...

Descripción completa

Detalles Bibliográficos
Autores principales: Schrijver, Lieske H, Mooij, Thea M, Pijpe, Anouk, Sonke, Gabe S, Mourits, Marian J E, Andrieu, Nadine, Antoniou, Antonis C, Easton, Douglas F, Engel, Christoph, Goldgar, David, John, Esther M, Kast, Karin, Milne, Roger L, Olsson, Håkan, Phillips, Kelly-Anne, Terry, Mary Beth, Hopper, John L, van Leeuwen, Flora E, Rookus, Matti A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9002279/
https://www.ncbi.nlm.nih.gov/pubmed/35048954
http://dx.doi.org/10.1093/jnci/djac004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9002279/
https://www.ncbi.nlm.nih.gov/pubmed/35048954
http://dx.doi.org/10.1093/jnci/djac004

Ejemplares similares